Fetal Embolization Feasible for Vein of Galen Malformation

2023-05-08
临床结果
MONDAY, May 8, 2023 -- Transuterine ultrasound-guided fetal embolization of vein of Galen malformation is feasible and eliminates postnatal pathophysiology, according to a research letter published online May 4 in Stroke.
Darren B. Orbach, M.D., Ph.D., from Boston Children's Hospital, and colleagues presented the first case of in utero embolization of a fetus diagnosed with vein of Galen malformation. The fetus was 34 2/7 weeks of gestational age at intervention, which involved ultrasound-guided percutaneous transuterine, transcranial embolization.
The researchers found immediate marked flow reduction in the varix and falcine sinus on intraprocedural ultrasound. A 43 percent reduction in total cardiac output was seen on fetal echocardiography after embolization. On fetal magnetic resonance imaging, diminution in caliber of the prosencephalic varix and width of the falcine sinus was seen (12.9 to 8 mm); there was no evidence of subdural, subarachnoid, or intraventricular hemorrhage or infarction. The infant was delivered by induction of vaginal birth at 34 4/7 gestational weeks due to premature rupture of membranes, with a birth weight of 1.9 kg. No cardiovascular support and no postnatal embolization were required by the 3-week-old infant. The infant had a normal neurological examination. On postnatal days 1 and 7, magnetic resonance imaging demonstrated further decrement in varix and falcine sinus caliber.
"This approach represents a paradigm shift in management of this challenging condition, from a strategy focused on reversing severe multiorgan pathophysiology after onset, to one focused instead on prevention via embolization in utero," the authors write.
One author is a consultant for Microbot Medical.
Abstract/Full Text
Posted May 2023
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。